Cytosorbents Medical Inc.

Princeton, NJ Part of Cytosorbents Corporation

UEI
LSF2KFUSY4K7
CAGE
5E0N2
Primary NAICS
339112 Surgical and Medical Instrument Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
Corporate family
SAM.gov registration date
Physical address
305 College Rd E, Princeton, NJ 08540, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $0
FY2025 $0
FY2024 -$109,827
FY2023 $149,873

Contract awards

Award Agency Obligated Awarded
Novel sorbent technology for the rapid treatment of acute joint injury and inflammation FA864923P0777 Air Force Research Laboratory (AFMC) $74,918
Novel oral sorbent therapy for the prevention and treatment of travelers diarrhea FA864923P0420 Air Force Research Laboratory (AFMC) $74,955
Award of cytosorbents DHA sbir PH III MED R & D contract for "integrating isoagglutinin reduction for a universal dried… W81XWH22C0046 Defense Health Agency $4,292,641
Medical research and development contract DHA sbir sequential PH II proposal no. H2S-0011 titled investigation of a… W81XWH21C0045 Defense Health Agency $1,499,987
Medical research and development contract DHA sbir phase II proposal no. H2S-0005 titled development of an effective… W81XWH20C0087 Medical Command (Army) $1,098,589

Latest 5 listed here. See the rest on GovTribe.

Grant awards

Award Agency Obligated Awarded
Novel extracorporeal therapy for the reversal of septic shock and restoring hemodynamic stability - rationale: sepsis… R43GM144973 National Institute of General Medical Sciences (NIH) $1,140,340
Demonstration of the safety and efficacy of a field-ready blood group antibody BGA adsorber in a porcine universal… W81XWH2210235 Defense Health Agency $1,977,024
Development of a highly efficient adsorber to remove anti-a and anti-B antibodies from blood and plasma for transfusion W81XWH2010712 Defense Health Agency $4,421,487
Prbc contaminant removal with hemocompatible porous polymer beads R44HL141928 National Heart Lung and Blood Institute (NIH) $2,570,301
Improving delayed evacuation and prolonged field care paradigms for severe burn injury via hemoadsorptive and enteral… W81XWH1720013 Defense Health Agency $717,966

Similar vendors

Vendor Location Primary NAICS
Daxor Pharmaceutical UEI QGB8LQAGTAH8 Oak Ridge, TN 334516 Analytical Laboratory Instrument Manufacturing
Desicorp, Inc. UEI KNA4L6N847S3 Louisville, KY 325414 Biological Product (except Diagnostic) Manufacturing
Nushores Biosciences LLC UEI FQWLSQZW4WK7 Little Rock, AR 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Bondwell Technologies LP UEI KC2RGD3DS457 College Station, TX 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Functional Circulation LLC UEI CWV6RGWLDVD3 Lake Mills, WI 339112 Surgical and Medical Instrument Manufacturing

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Cytosorbents Medical Inc., doing business as Cytosorbents, is a for-profit manufacturer that provides medical devices and technologies to federal agencies through contracts and grants. The company develops blood purification technologies to treat critical care conditions.

Through federal contracts, Cytosorbents has provided the Defense Health Agency, Department of the Army, and Department of the Air Force with medical research and prototype development services under the Small Business Innovation Research (SBIR) and Small Business Technology Transfer Research (STTR) programs. As a small business, several of its awards have been set aside for Cytosorbents as the prime contractor. Specific goods and services provided include an extracorporeal cytokine adsorber to treat septic shock, a potassium adsorber to treat hyperkalemia, and an adsorber to remove anti-A and anti-B antibodies from blood for transfusion. Cytosorbents has partnered with federal agencies to further develop these medical device technologies.

Through federal grants, Cytosorbents Medical has received research project funding from the National Institutes of Health and Department of the Army Medical Command to demonstrate the safety and efficacy of its blood purification devices. This includes a $1.1 million project from NIH to evaluate a combination cytokine and endotoxin adsorber therapy for treating septic shock in animal models. It also includes a $2 million project grant from the DoD to test its blood group antibody adsorber for enabling universal blood transfusions in a porcine model. For both awards, Cytosorbents is the prime grantee responsible for conducting the research to advance its medical technologies.

Quick answers

Is Cytosorbents Medical Inc. registered in SAM.gov?

Yes. Cytosorbents Medical Inc.'s SAM.gov registration is active through December 12, 2026.

What is Cytosorbents Medical Inc.'s CAGE code?

Cytosorbents Medical Inc.'s CAGE code is 5E0N2, and its Unique Entity ID (UEI) is LSF2KFUSY4K7.

How much has Cytosorbents Medical Inc. received in federal contracts?

Federal contracts obligated $40,046 to Cytosorbents Medical Inc. in fiscal years 2023 through 2027.

What is Cytosorbents Medical Inc.'s most recent federal award?

Cytosorbents Medical Inc.'s most recent federal contract award is Novel sorbent technology for the rapid treatment of acute joint injury and inflammation (FA864923P0777), from Air Force Research Laboratory (AFMC), on May 12, 2023.

On GovTribe

See Cytosorbents Medical Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe